Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMVT with free AI briefings, catalyst countdowns, and dilution alerts.

IMVT · Immunovant, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$722.3M Cash on Hand
20.9mo Cash Runway
Follow IMVT by email Get an email when IMVT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMVT, unsubscribe in one click. Privacy

📣 What IMVT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Batoclimab Thyroid Eye Disease Phase 3 · NCT05517447 Terminated
Imeroprubart (IMVT-1402) Generalized Myasthenia Gravis Phase 3 · NCT07039916 Recruiting
Batoclimab 680 milligrams (mg) subcutaneous… Chronic Inflammatory Demyelinating Polyneuropathy Phase 2 · NCT05581199 Terminated
IMVT-1401 Graves Disease Phase 2 · NCT05907668 Completed
RVT-1401 Myasthenia Gravis Phase 2 · NCT03863080 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMVT holds $722.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $103.8M/quarter from operations, an estimated runway of 20.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMVT files for a raise →

👥 Who Owns IMVT

Insiders 1.2% Other 5%+ holders 54.8% Institutions (318 holders) 44% Public and other holders 0%
HolderTypeShares% of sharesAs of
Roivant Sciences Ltd. 5%+ holder (13D) 113,327,007 54.76% 2025-12-12
Frank Torti
Director · +88,325 options
Insider 1,009,228 0.49% 2026-04-07
Eric Venker
Chief Executive Officer, Director · +1.26M options
Insider 257,075 0.12% 2026-10-01
Tiago Girao
Chief Financial Officer · +283,505 options
Insider 234,192 0.11% 2026-10-28
Melanie Gloria
Chief Operating Officer · +121,063 options
Insider 217,060 0.10% 2026-10-07
Jay S Stout
Chief Technology Officer · +96,851 options
Insider 198,937 0.10% 2026-10-21
Tuyl Christopher Van
Chief Legal Officer · +113,527 options
Insider 175,218 0.08% 2026-10-07
Atul Pande
Director · +69,242 options
Insider 136,731 0.07% 2026-11-11
Douglas J. Hughes
Director · +7,061 options
Insider 134,653 0.07% 2026-04-07
Andrew J. Fromkin
Director · +7,061 options
Insider 74,382 0.04% 2026-05-28
Jake Bauer
Director · +7,061 options
Insider 38,896 0.02% 2026-04-07
Robert Graham Susman
Director · +7,061 options
Insider 36,394 0.02% 2026-05-01

Share count 206,947,758 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMVT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMVT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.